Vivos Inc. Reports Revenue Increase to $41,748 but Faces Continued Operational Losses

Vivos Inc. reported its financial results for the six months ending June 30, 2025, revealing a significant increase in revenue but continued operational losses. The company generated $41,748 in revenue during this period, a substantial rise from $18,000 in the same period last year. However, the cost of goods sold also increased sharply to $85,583, resulting in a gross loss of $43,835 compared to a gross profit of $1,220 in the prior year. The net loss for the first half of 2025 was $1,480,209, up from a loss of $1,061,997 in the same period of 2024.

Operating expenses for Vivos Inc. rose to $1,494,470 in the first half of 2025, compared to $1,100,659 in the previous year. This increase was primarily driven by higher professional fees, payroll expenses, and research and development costs, reflecting the company's ongoing investment in product development and regulatory compliance. The company reported a notable increase in professional fees, which rose from $683,452 to $946,723, as well as a rise in research and development expenses from $157,109 to $227,246.

In terms of operational developments, Vivos Inc. has made strides in its strategic initiatives, particularly in the veterinary oncology market with its IsoPet® product. The company has begun to charge clinics for certification services, which is expected to enhance revenue streams. As of June 30, 2025, Vivos had $2,660,590 in cash, an increase from $2,212,548 at the end of 2024, indicating improved liquidity. The company also reported a working capital increase to $2,679,098 from $2,147,247, suggesting a stronger financial position.

Looking ahead, Vivos Inc. anticipates requiring approximately $3 million annually to maintain operations and an additional $9 million over the next three years to fund FDA approval processes and clinical trials. The company is actively pursuing funding through its Regulation A+ offerings, having raised $1,500,000 in the first half of 2025. Vivos plans to expand its product offerings and geographic reach, particularly in India, where it aims to establish a business entity and conduct clinical trials. However, the company faces significant challenges, including the need for ongoing capital and the uncertainty of regulatory approvals, which could impact its ability to continue operations.